ArticleCureus2025
Giant Prolactinoma Resistant to High-Dose Cabergoline in a Young Male Lost to Follow-Up.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pituitary adenomas are neoplasms of the adenohypophysis (anterior pituitary gland) that can cause a multitude of symptoms secondary to the hormones they secrete (functioning adenomas) or mass effect on the optic chiasma (non-functioning adenomas). Functioning adenomas can secrete prolactin, growth hormone, adrenocorticotrophic hormone (ACTH) or thyroid-stimulating hormone, with some adenomas co-secreting more than one. This can lead to symptoms of prolactinoma, acromegaly, Cushing's disease, and TSHoma dependent on the elevated hormone. In non-functioning adenomas, visual changes, and headaches are seen. This case report follows a 19-year-old male who presented with visual acuity loss and persistent headaches, later diagnosed as a pituitary macroadenoma with a prolactin level of 794,560 mIU/L. He was subsequently treated with off-label cabergoline over three times the therapeutic limit for approximately 10 years. He was unfortunately lost to follow-up and unmonitored during this time, where he developed an impulse control disorder and showed inadequate response to the high-dose cabergoline. At the time of re-presenting to outpatient clinics, his adenoma was found to be extending into the cavernous sinuses with tentorial involvement, reducing the potential for surgical management. Discussions around medical, surgical, and radiotherapeutic management are being raised in light of this cabergoline resistance and placement. The case overall highlights the complexities of managing giant, dopamine agonist-resistant prolactinomas, especially in the setting of delayed follow-up, incomplete biochemical control, and neuropsychiatric side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.